Form 4: Nascent Biotech CFO Acquires 96,000 Shares at $0.09 as Part of Employment Contract

Lowell Thomas Holden, CFO of Nascent Biotech Inc., acquired 96,000 shares of common stock at $0.09 per share on June 30, 2024, as part of his employment contract.

Summary

• On June 30, 2024, Lowell Thomas Holden, the CFO of Nascent Biotech Inc., acquired 96,000 shares of the company's common stock.
• The shares were acquired at a price of $0.09 per share.
• This transaction was part of Mr. Holden's employment contract with the company.
• Following the transaction, Mr. Holden directly owns 10,005,477 shares of Nascent Biotech Inc.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard transaction related to an employment contract. The CFO's increased stake could be seen as a positive signal, but it's not necessarily indicative of significant future performance.

Positives

• The acquisition of shares by the CFO demonstrates confidence in the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and alignment with shareholder interests.

Stakeholder Impact

• Shareholders may view the CFO's increased stake as a positive sign of confidence in the company's future.

Key Dates

Keywords

Form 4, insider trading, share acquisition, Lowell Thomas Holden, CFO, Nascent Biotech Inc., NBIO, employment contract, common stock